公开(公告)号：EP2253709B1

公开(公告)日：2018-04-11

申请号：EP10008120.7

申请日：2003-05-14

申请人： Bavarian Nordic A/S

发明人： Leyrer, Sonja ,  Howley, Paul

IPC分类号： C07K14/005 ,  C12N15/86 ,  A61K39/00 ,  A61K35/76

CPC分类号： A61K35/76 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2770/24122 ,  C12N2840/20 ,  C12N2840/203 ,  Y02A50/386 ,  Y02A50/39

摘要： The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing an immune response in a living animal, including a human, is provided.

公开(公告)号：EP2812434B1

公开(公告)日：2018-03-28

申请号：EP13708667.4

申请日：2013-02-08

申请人： Bavarian Nordic A/S

发明人： BAUER, Stefan ,  HOCHREIN, Hubertus ,  KIRSCHNING, Carsten

IPC分类号： C12N15/117 ,  A61K31/7105 ,  A61K39/39 ,  A61P37/02 ,  A61P31/04

CPC分类号： C12N15/1138 ,  A61K31/7105 ,  A61K39/085 ,  A61K39/092 ,  A61K39/39 ,  C12N15/117 ,  C12N2310/14 ,  C12N2310/17 ,  C12N2320/30 ,  C12N2330/10

摘要： The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids.

公开(公告)号：EP3188752A2

公开(公告)日：2017-07-12

申请号：EP15763853.7

申请日：2015-09-03

申请人： Bavarian Nordic A/S

发明人： VOLKMANN, Ariane ,  STEIGERWALD, Robin ,  HOCHREIN, Hubertus ,  DIRMEIER, Ulrike ,  LAUTERBACH, Henning ,  HAUSMANN, Jürgen

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/545 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2760/14134

摘要： The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

摘要翻译： 本发明涉及包含针对丝状病毒感染的基于重组修饰的痘苗病毒安卡拉（基于MVA的）疫苗的改进的丝状病毒疫苗，并涉及相关产品，方法和用途。 具体而言，本发明涉及包含至少一种编码马尔堡病毒（MARV）或埃博拉病毒糖蛋白的抗原决定簇的异源核苷酸序列的基因工程（重组）MVA和FPV载体。 具体而言，本发明涉及包含埃博拉病毒糖蛋白和病毒粒子蛋白40的重组MVA。本发明还涉及其产品，方法和用途以及MVA和基因工程（重组）FPV的初免/加强方案，例如适于诱导 受试者中的保护性免疫应答。

公开(公告)号：EP1420822B2

公开(公告)日：2017-07-05

申请号：EP03732280.7

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： CHAPLIN, Paul ,  SUTER, Mark ,  ACKERMANN, Mathias ,  FRANCHINI, Marco ,  VOLLSTEDT, Sabine ,  HEFTI, Hans, Peter

IPC分类号： A61K39/285 ,  A61K39/245

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

摘要翻译： 本发明涉及使用病毒制备用于接种或治疗新生儿或产前动物（包括人）的药物，其中所述病毒能够感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人类）中复制为感染性后代病毒。 该病毒优选是改良的安卡拉痘苗病毒。 具体地说，本发明涉及新生儿接种疫苗以防止与用于疫苗接种的病毒属于同一病毒组的病毒感染。 此外，本发明涉及新生儿针对选自外来抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明进一步涉及如上定义的病毒用于增加激活树突细胞或其前体细胞和/或增加树突细胞或其前体细胞数量和/或增加产生和/或细胞的因子水平 干扰素（IFN）或IL-12的含量。

公开(公告)号：EP2788021A1

公开(公告)日：2014-10-15

申请号：EP12794878.4

申请日：2012-11-30

申请人： Bavarian Nordic A/S

发明人： CHAPLIN, Paul ,  STEIGERWALD, Robin

IPC分类号： A61K39/02 ,  C12N15/86

CPC分类号： C12N15/86 ,  A61K39/07 ,  A61K2039/53 ,  A61K2039/6037 ,  C07K2319/55 ,  C12N2710/24043 ,  C12N2710/24143

摘要： The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

摘要翻译： 本发明涉及包含用于改善抗原免疫原性的破伤风毒素片段C和相关方法和用途的重组痘病毒。 具体而言，本发明通常涉及包含可操作地连接到细菌抗原决定簇的破伤风毒素片段C（TTC）编码序列的基因工程（重组）痘病毒载体及其用途，例如影响受试者的免疫应答 。

公开(公告)号：EP2486138A1

公开(公告)日：2012-08-15

申请号：EP10765582.1

申请日：2010-10-06

申请人： Bavarian Nordic A/S

发明人： CHAPLIN, Paul ,  NICHOLS, Richard

IPC分类号： C12N15/863 ,  A61K39/21

CPC分类号： A61K39/12 ,  A61K39/21 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/57 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16334

摘要： The present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in the viral genome one or more expression cassettes for the expression of HIV proteins selected from Gag, Pol, Tat, Vif, Vpu, Vpr, Rev and Nef or a part or a derivative thereof or selected from Gag, Pol, Vpu, Vpr, Rev and Nef or a part or a derivative thereof for use as medicament or vaccine and its use for the treatment and/or prevention of HIV infections and AIDS.

公开(公告)号：EP2345665A3

公开(公告)日：2012-02-15

申请号：EP11000882.8

申请日：2002-11-20

申请人： Bavarian Nordic A/S ,  Venture Technologies Sdn Bhd

发明人： Howley, Paul ,  Leyrer, Sonja ,  Cardosa, Mary Jane ,  Henry Sum, Magdeline Sia

IPC分类号： C07K14/18

CPC分类号： C07K14/005 ,  A61K2039/5256 ,  A61K2039/545 ,  C12N2710/24143 ,  C12N2770/24022 ,  C12N2770/24122 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394

摘要： The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors, comprising said DNA and vaccines containing or expressing a Flavivirus NS1.

公开(公告)号：EP2204179A3

公开(公告)日：2010-12-22

申请号：EP10158052.0

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL·12.

公开(公告)号：EP1845164B1

公开(公告)日：2010-06-16

申请号：EP07014231.0

申请日：2004-01-17

申请人： Bavarian Nordic A/S

发明人： Leyrer, Sonja, Dr.

IPC分类号： C12N15/863 ,  A61K39/285

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2710/24143

摘要： The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.

公开(公告)号：EP2152857A1

公开(公告)日：2010-02-17

申请号：EP08749144.5

申请日：2008-04-25

申请人： Bavarian Nordic A/S

发明人： HOCHREIN, Hubertus ,  O'KEEFFE, Meredith

IPC分类号： C12N5/06

CPC分类号： C12N5/0639

摘要： A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor (M-CSF) is provided. M-CSF induces DCs to differentiate into Subtypes, for example plasmacytoid DCs and conventional DCs. Said differentiation is independent of Fms-like-Tyrosine- Kinase 3-Ligand (FL) and/or Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF). Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for Cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.